Topics:

Renal Cell Carcinoma

New Target for Fighting Clear Cell RCC?

Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma, neuronal pentraxin 2 (NPTX2).

Renal Cell Carcinoma

A new study shows yet another link between increasing body mass index (BMI) and the risk of several common cancers, including kidney cancer.

Expression of microRNA (miR)-23b/27b cluster has been linked with increased risk for clear cell RCC disease progression, and may be a predictor of poor survival.

Researchers have identified a key gluconeogenic enzyme, the absence of which in clear cell renal cell carcinoma (RCC) may explain the uncontrolled cell growth present in cancer cells compared with normal kidney cells.

Results of a head-to-head comparison of first-line treatment of metastatic renal cell carcinoma with the mTOR inhibitor everolimus or VEGF inhibitor sunitinib showed that everolimus did not meet noninferiority requirements as a first-line therapy.

Scientists have discovered a new molecular target for therapy to fight clear cell renal cell carcinoma, neuronal pentraxin 2 (NPTX2).

Among patients with clear cell renal cell carcinoma who had undergone nephrectomy, patients with diabetes were found to have a significantly decreased cancer-specific and overall survival.

A 16-gene Recurrence Score was found to be significantly predictive of recurrence-free interval and survival in patients with stage I-III clear cell renal cell carcinoma who have undergone nephrectomy.

Pages

Subscribe to Renal Cell Carcinoma on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.